^
    Back
    Association details:
    Biomarker:MYD88 mutation
    Cancer:Lymphoma
    Drug:Rituxan (rituximab) (CD20 inhibitor) +
    Yinuokai (orelabrutinib) (BTK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    ASH 2022
    Title:

    558 Orelabrutinib, Rituximab, and High-Dose Methotrexate (HD-MTX) in Newly Diagnosed Primary Central Nervous System Lymphoma (PCNSL): A Retrospective Analysis on Efficacy, Safety, and Biomarker

    Published date:
    11/03/2022
    Excerpt:
    ...18 pts (81.8%, 18/22) had an MYD88 mutation and achieved an ORR of 100% (CR, 55.6%)….This retrospective data suggested that orelabrutinib combined with RM had an encouraging anti-tumor activity in newly diagnosed PCNSL pts, with a toleratable safety profile.
    Secondary therapy:
    methotrexate
    DOI:
    https://doi.org/10.1182/blood-2022-165710